本文章的学术内容和语言评估
本文章的CrossCheck查重和Google搜索
本文章的学术规范
本文章的补充材料
本文章的引用
本文章的通讯作者
本文章的研究领域
本文章的类型
本文章的开放获取政策
本文章的Google引用次数
本文章的点击和下载次数
- 本文章浏览次数 (8221)
All Articles published online
|
Featured Article
|
Publishing Process of This Article
|
Apr 7, 2025 (publication date) through Feb 3, 2026
本文章的被引频次
本文章的期刊信息
出版物名称
World Journal of Gastroenterology
ISSN
1007-9327
本文章的出版商
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| Yang XE, Zhang SJ, Liu Y, Yao SY, Zhang SX, Liu XM, Liang LX, Wang F. Amoxicillin high-dose dual therapy for Helicobacter pylori primary eradication: Proton pump inhibitor and potassium-competitive acid blocker, which’s better? World J Gastroenterol 2025; 31(13): 100863 [PMID: 40248055 DOI: 10.3748/wjg.v31.i13.100863] |
|
|
|
| ©2004-2026 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA | |
| For: | Yang XE, Zhang SJ, Liu Y, Yao SY, Zhang SX, Liu XM, Liang LX, Wang F. Amoxicillin high-dose dual therapy for Helicobacter pylori primary eradication: Proton pump inhibitor and potassium-competitive acid blocker, which’s better? World J Gastroenterol 2025; 31(13): 100863 [PMID: 40248055 DOI: 10.3748/wjg.v31.i13.100863] |
|---|---|
| URL: | https://www.wjgnet.com/1009-3079/full/v31/i13/100863.htm |
| 编号 | Citing Articles |
| 1 |
Karolina Kornatowska, Edyta Hańczyk, Dawid Piecuch, Szymon Kopciał, Natalia Pawelec, Weronika Mazur, Mateusz Tyniec, Kamal Morshed. A Novel Approach to H. pylori Eradication: A Narrative Review of Vonoprazan-Based Therapies. Gastroenterology Insights 2025; 16(3): 35 doi: 10.3390/gastroent16030035
|
| 2 |
Xue Fan, Yanyan Shi, Yuan Li, Xiangchun Lin. Comparison of Vonoprazan and Low-Dose Amoxicillin Dual Therapy with Bismuth-Containing Quadruple Therapy for Naïve Helicobacter pylori Eradication: A Single-Center, Open-Label, Randomized Control Trial. Antibiotics 2025; 14(10): 990 doi: 10.3390/antibiotics14100990
|
| 3 |
Iqbal Taufiqqurrachman, Ari Fahrial Syam, Hasan Maulahela, Murdani Abdullah, Takashi Matsumoto, Muhammad Miftahussurur, Yoshio Yamaoka. Comparative efficacy, safety and compliance with dual, triple and quadruple therapy as the first-line treatment regimens for Helicobacter pylori eradication: a systematic review and network meta-analysis. BMJ Open Gastroenterology 2026; 13(1): e002037 doi: 10.1136/bmjgast-2025-002037
|
| 4 |
Jun-Hyung Cho. Tegoprazan–Amoxicillin Dual Therapy for Clarithromycin-Resistant Helicobacter pylori: A Feasibility Pilot Study. Microorganisms 2025; 13(10): 2408 doi: 10.3390/microorganisms13102408
|
| 5 |
Wei-Chen Tai, Lung-Sheng Lu, Shih-Cheng Yang, Hsin-Ming Wang, Cheng-Kun Wu, Chih-Chien Yao, Pao-Yuan Huang, Yu-Chi Lee, Seng-Kee Chuah, Chih-Ming Liang.
Comparative efficacy and safety of vonoprazan versus esomeprazole-based high-dose dual therapies for first-line
Helicobacter pylori
eradication: a randomized controlled trial
. Therapeutic Advances in Gastroenterology 2025; 18 doi: 10.1177/17562848251378066
|
| 6 |
Vidya Suresh, Amritavarshini Sreekumar, Anil Kumar, Shine Sadasivan, Raja Biswas, Lalitha Biswas. Therapeutic advances and future directions in Helicobacter pylori eradication. Frontiers in Microbiology 2025; 16 doi: 10.3389/fmicb.2025.1652943
|